Category Archives: Non-U.S. Practice

One step ahead and one step backward for the EU patent

The following is a contribution from Camilla Rendal Nielsen of Zacco Denmark A/S 1.   The EU Competiveness Council have authorised “enhanced cooperation” in the area of unitary patent protection, and. 2.   The EU court now states that the proposed Patents Court … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , , , , , , | Leave a comment

Canadian Ruling Supports “Antibody Exception”

In my recent post on the Centocor v. Abbott decision, I noted that the Fed. Cir. had at least preserved the “antibody exception,” which I define as permitting broad claims to structurally uncharacterized antibodies (monoclonal and polyclonal) if the structure … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , , , , , , , | Leave a comment

A Scheme For Maximizing The Benefits Available Under The Patent Prosecution Highway (PPH)

This post is from Mark Horsburgh of Fisher Adams Kelly in Australia. Summary File in Australia first; Request expedited examination (report issues within 3 months); Address objections and obtain acceptance; File in USA and request entry to PPH (faster and … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , , , , , , | Leave a comment

Mumbo Jumbo: The Patentability of Biological Materials In Australia

From Vaughn Barlow of Pizzeys Patent and Trade Mark Attorneys. 1. Introduction The Patent Amendment (Human Genes and Biological Materials) Bill (2010) is currently being debated before the Australian parliament. The Bill seeks to ban the patenting of all biological … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , , , , , , , | Leave a comment